Pevonedistat and Azacitidine in MDS or MDS/MPN Patients Who Fail Primary Therapy With DNA Methyl Transferase Inhibitors
Status:
Suspended
Trial end date:
2023-07-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the treatment combination of pevonedistat and azacitidine in the
setting of DNA methyltransferase inhibitor(s) failure in patients with relapsed/refractory
myelodysplastic syndrome or myelodysplastic syndrome/myeloproliferative neoplasm.